Author Interviews, JAMA, Opiods, Pediatrics, UCSD / 17.07.2019
Teens: Nonmedical Prescription Opioid Use Associated With Subsequent Heroin Use
MedicalResearch.com Interview with:
[caption id="attachment_50286" align="alignleft" width="200"]
Dr. Kelley-Quon[/caption]
Lorraine Kelley-Quon, MD, MSHS, FAAP
Assistant Professor | Division of Pediatric Surgery
Children's Hospital Los Angeles
Department of Surgery & Preventive Medicine
Keck School of Medicine of USC
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Prescription opioids are pharmacologically similar to heroin, and previous research has shown an association between nonmedical opioid use and heroin use.
This is the first study to follow a group of teenagers through all 4 years of high school and identify an association between nonmedical prescription opioid use and later heroin use.
Dr. Kelley-Quon[/caption]
Lorraine Kelley-Quon, MD, MSHS, FAAP
Assistant Professor | Division of Pediatric Surgery
Children's Hospital Los Angeles
Department of Surgery & Preventive Medicine
Keck School of Medicine of USC
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Prescription opioids are pharmacologically similar to heroin, and previous research has shown an association between nonmedical opioid use and heroin use.
This is the first study to follow a group of teenagers through all 4 years of high school and identify an association between nonmedical prescription opioid use and later heroin use.




Dr. Zhu[/caption]
Wenjia Zhu, PhD.
Marshall J. Seidman Fellow
Department of Health Care Policy
Harvard Medical School
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: The current opioid epidemic continues to cause deaths and tremendous suffering in the United States, driven in large part by overuse of prescription opioids. Of special concern are new opioid prescriptions, i.e. opioids given to patients who have not used opioids before, which research tells us are an important gateway to long-term opioid use, misuse, overdoes and death. Recently, in their efforts to curb over prescribing of opioids, the CDC issued guidelines (December 2015 in draft form; March 2016 in final version) to encourage opioid prescribers to limit the use, duration and dose of opioids, particularly opioids to first-time users. Despite these, little is known about the prescribing of opioids to first-time users on a national scale, particularly among commercially insured patients.
In this study, we examined national monthly trends in the rate at which opioid therapy was started among commercially insured patients. Using administrative claims from Blue Cross Blue Shield Association commercial insurers from 2012 to 2017, we analyzed more than 86 million commercially insured patients across the United States.
Dr. Kessler[/caption]
MedicalResearch.com Interview with:
Lawrence M. Kessler, PhD Research Assistant Professor
[caption id="attachment_47359" align="alignleft" width="112"]
Dr. Harris[/caption]
Matthew C. Harris, PhD Assistant Professor
Boyd Center for Business and Economic Research and Department of Economics
The University of Tennessee
MedicalResearch.com: What is the background for this study?
Response: Motivation for this study came from Co-Author, Matt Murray, who was at a speaking engagement and heard a community business leader say “we’ve got jobs, but no one is applying, could opioids be a contributing factor?” This led to a conversation back at the Boyd Center between us and Matt Murray, where we decided that if we could get data on prescription rates, we could answer this question empirically.
We started by contacting each state agency in charge of their respective prescription drug monitoring program to see if they’d be willing to share county-level data on prescription opioid rates. From this letter-writing campaign we received data from 10 states, which formed the basis for our analysis. As time went on, new data was made publicly available and we were able to expand the analysis to all 50 states.